Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Sputum

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    624 result(s) found for: Sputum. Displaying page 8 of 32.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    EudraCT Number: 2011-000801-39 Sponsor Protocol Number: PsAer-IgY Start Date*: 2011-08-31
    Sponsor Name:Mukoviszidose Institute gGmbH
    Full Title: Prospective randomized, placebo-controlled, double blind, multicenter study (phase III) to evaluate clinical efficacy and safety of avian polyclonal anti-Pseudomonas antibodies (IgY) in prevention ...
    Medical condition: Cystic fibrosis (CF) is a chronic and progressive genetic disease of the body's exocrine glands. CF especially affects the respiratory system. A common effect leads to massive production of abnorma...
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004850 10011764 Cystic fibrosis NOS LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) BE (Completed) IT (Completed) IE (Completed) HU (Completed) AT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-000442-38 Sponsor Protocol Number: TR02-109 Start Date*: 2011-10-03
    Sponsor Name:Insmed Incorporated
    Full Title: Randomized, placebo-controlled, double-blind, multicenter study to assess the efficacy, safety and tolerability of Arikace™ in Cystic Fibrosis patients with chronic infection due to Pseudomonas Aer...
    Medical condition: Pseudomonas aeruginosa pulmonary infection / colonisation in patients with cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10011763 Cystic fibrosis lung PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Prematurely Ended) PL (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-004872-76 Sponsor Protocol Number: RECUT-Trial Start Date*: 2020-05-07
    Sponsor Name:Medizinische Universtitätsklinik, Kantonsspital Baselland
    Full Title: Reduction of corticosteroid use in outpatient treatment of exacerbated COPD – a randomized, double-blind, non-inferiority study (The “RECUT”-Trial)
    Medical condition: acute exacerbation of COPD; acute exacerbation (defined solely by clinical parameters according to the Anthonisen criteria, meaning ≥2 of the following: change of baseline dyspnea, change of cough,...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10010953 COPD exacerbation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000495-28 Sponsor Protocol Number: 132 Start Date*: 2017-05-18
    Sponsor Name:Respiratory Research Unit, Bispebjerg University Hospital
    Full Title: SIGNATURE - the 6-gene signature as a predictor of response to treatment in severe asthma and ACOS
    Medical condition: Severe asthma and astma-COPD overlap syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10077006 Asthma-COPD overlap syndrome LLT
    20.0 100000004855 10003561 Asthma, unspecified LLT
    20.0 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-011740-19 Sponsor Protocol Number: GS-US-205-0127 Start Date*: 2015-02-02
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: Phase 3b Randomized, Double-Blind, Placebo-Controlled Two-Part Trial to Assess the Safety and Efficacy of Continuous Aztreonam for Inhalation Solution (AZLI) in Subjects with Cystic Fibrosis (CF) a...
    Medical condition: Cystic Fibrosis subjects with chronic Burkholderia spp. infection of the airways.
    Disease: Version SOC Term Classification Code Term Level
    17.1 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-004103-10 Sponsor Protocol Number: CTP-G007.05, Protocol Amendment 02 Start Date*: 2006-05-03
    Sponsor Name:PARI Pharma GmbH
    Full Title: Randomized, open labeled, multi center, active controlled, parallel 28 days safety and bioavailability study of Tobramycin 100 PARI nebulized with eFlow® versus TOBI® nebulized with PARI LC PLUS in...
    Medical condition: Cystic Fibrosis with Pseudomoas aeuriginosa infection
    Disease: Version SOC Term Classification Code Term Level
    8.1 10011763 Cystic fibrosis lung LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001968-78 Sponsor Protocol Number: ADC4022_CLIN_02P Start Date*: 2007-07-20
    Sponsor Name:Argenta Discovery Ltd.
    Full Title: A Phase II, Randomised, Double-Blind, Placebo-Controlled Pilot Efficacy Study of ADC4022 (Theophylline Solution for Inhalation) on Markers of Pulmonary Inflammation in Subjects with Moderate to Sev...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-013163-18 Sponsor Protocol Number: R014 Start Date*: 2009-08-11
    Sponsor Name:REVOTAR Biopharmaceuticals AG
    Full Title: A double-blind, placebo controlled, randomized, cross-over Phase IIa study to evaluate the effect of Bimosiamose on ozone induced sputum neutrophilia in healthy subjects.
    Medical condition: healthy subjects
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    9.1 10003553 Asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-004923-34 Sponsor Protocol Number: RSV-MVA-004 Start Date*: 2022-07-07
    Sponsor Name:Bavarian Nordic A/S
    Full Title: A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN®-RSV Vaccine in Adults ≥60 Years of Age
    Medical condition: respiratory syncytial virus disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10066742 Respiratory syncytial virus infection prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004558-13 Sponsor Protocol Number: Z7224L02 Start Date*: 2017-05-30
    Sponsor Name:Zambon S.p.A.
    Full Title: A double-blind, placebo controlled, multicentre, clinical trial to investigate the efficacy and safety of 12 months of therapy with inhaled Promixin® (colistimethate sodium) in the treatment of sub...
    Medical condition: Non-cystic fibrosis bronchiectasis chronically infected with Pseudomonas aeruginosa
    Disease: Version SOC Term Classification Code Term Level
    19.1 10038738 - Respiratory, thoracic and mediastinal disorders 10006445 Bronchiectasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) PL (Completed) DE (Completed) PT (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-002473-19 Sponsor Protocol Number: PNEU-ASTHMA-02 Start Date*: 2018-11-13
    Sponsor Name:Cliniques Universitaires Saint-Luc
    Full Title: PREDICTIVE FACTORS AND MAGNITUDE OF RESPONSE TO OMALIZUMAB AND MEPOLIZUMAB IN ALLERGIC AND EOSINOPHILIC SEVERE ASTHMA: A MULTICENTER PRAGMATIC TRIAL IN BELGIUM
    Medical condition: Adult patients (at least 18yrs-old) with severe asthma and eligible for both XOLAIR and NUCALA therapies, and agreeing on participating (signature of a written informed consent).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-001401-41 Sponsor Protocol Number: TAPAS-2014 Start Date*: 2014-07-29
    Sponsor Name:
    Full Title: Targeting Antibiotics to Pseudomonas Aeruginosa in Small airways (TAPAS) study in patients with cystic fibrosis
    Medical condition: Cystic Fibrosis and chronic infection with Pseudomonas aeruginosa
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002677-38 Sponsor Protocol Number: CTX-4430-CF-201 Start Date*: 2016-02-04
    Sponsor Name:Celtaxsys Inc.
    Full Title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 Administered Orally Once-Daily for 48 Weeks...
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011763 Cystic fibrosis lung PT
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) IT (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-002836-25 Sponsor Protocol Number: QGUY/2004/IL 4-13/01 Start Date*: 2004-12-15
    Sponsor Name:Aerovance Inc.
    Full Title: A Phase IIa Study To Investigate The Effects of AER 001on Antigen Challenge In Atopic Asthmatic Subjects Following Repeated Administration.
    Medical condition: Asthma is characterised by an infiltration of the bronchial mucosa with activated T-lymphocytes (T-cells), eosinophils, and to a lessor extent polymorphonuclear leukocytes.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-003561-13 Sponsor Protocol Number: cro488 Start Date*: 2006-12-04
    Sponsor Name:imperial college
    Full Title: Reversal of steroid insensitivity in COPD by theophylline
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-000418-20 Sponsor Protocol Number: D1450C00001 Start Date*: 2006-04-06
    Sponsor Name:AstraZeneca AB
    Full Title: A 4-week randomized, double-blind, placebo controlled, parallel group, phase II study to assess the efficacy and safety of gefitinib tablets, 250 mg once daily (OD), in adult patients with moderate...
    Medical condition: Moderate Chronic Obstructive Pulmonary Disease (COPD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) FI (Prematurely Ended) NO (Prematurely Ended) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-003833-15 Sponsor Protocol Number: MEU04/118A Start Date*: 2006-11-21
    Sponsor Name:South Manchester University NHS Trust [...]
    1. South Manchester University NHS Trust
    2. Medicines Evaluation Unit
    3. University of Manchester
    Full Title: A randomised parallel group study to investigate the effect of Seretide withdrawal in COPD using non-invasive biomarkers and physiological measurements
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-022040-20 Sponsor Protocol Number: Statin_2010 Start Date*: 2010-12-17
    Sponsor Name:NHS Lothian [...]
    1. NHS Lothian
    2. University of Edinburgh
    Full Title: A Randomised Controlled Trial of Atorvastatin as an Anti-Inflammatory Agent in Non-Cystic Fibrosis Bronchiectasis
    Medical condition: The aim of this randomised double blind controlled study to evaluate the efficacy of 6 months treatment with atorvastatin versus placebo in patients with clinically significant bronchiectasis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10006445 Bronchiectasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-006061-86 Sponsor Protocol Number: K/604 Start Date*: 2009-12-17
    Sponsor Name:Cassella-med
    Full Title: Multizentrischer, randomisierter, doppelblinder, Placebo-kontrollierter Parallelgruppenvergleich zum Nachweis der Wirksamkeit und Unbedenklichkeit von Cineol im Rahmen der Therapie bei Patienten mi...
    Medical condition: acute bronchitis with productive cough
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-000653-23 Sponsor Protocol Number: TMC207-TiDP13-C210 Start Date*: 2012-06-13
    Sponsor Name:Janssen Infectious Diseases BVBA
    Full Title: A Phase III placebo-controlled, double-blind, randomized trial to evaluate the efficacy and safety of TMC207 in subjects with sputum smear-positive pulmonary infection with multi-drug resistant Myc...
    Medical condition: Multi-drug resistant tuberculosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10044755 Tuberculosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Prematurely Ended) LV (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 17:04:00 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA